Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Dr. Chamie Interview - Quilt 3.032 study (N-803 + BCG)

<< Previous

Bullboard Posts

Next >>

Comment by ScienceFirston Apr 20, 2023 1:58pm

107 Views

Post# 35405736

RE:RE:Dr. Chamie Interview - Quilt 3.032 study (N-803 + BCG)

With Eoganacht's new interview where InmunityBio mentions that they initially had a CR of 55%, before retreating, this means we already equal them, even with our latest data that contains 12 undertreated patients out of 25 patients (so 48% of our pool of patients), where we got 53% of CR.

With only 2 treatments over the many for the N-803+BCG(see below), and not having to rely on BCG, we'll be top of class.

BCG and N-803 will be mixed together (with saline) and administered via intravesical instillation weekly for 6 consecutive weeks (induction). After the first disease assessment, eligible patients will receive either a 3-week maintenance course or a 6-week re-induction course (second treatment period) at Month 3. Eligible patients will continue to receive maintenance treatment in the third treatment period at Months 6, 9, 12, and 18. Eligible patients have the option to receive maintenance treatment in the fourth treatment period at Months 24, 30, and 36.